Abstract
Following the well-documented serendipitous discovery of the antitumour properties of cis-diamminedichloro platinum(II) (cisplatin) in the mid 1960s (see Rosenberg, 1985, for a review), the drug was introduced into clinical practice in 1971. While the introduction of cisplatin has undoubtedly made a dramatic impact on the response rates (and long-term survival) obtained for patients presenting with some tumour types (notably testicular teratoma and ovarian carcinoma), much effort has been, and continues to be, expended towards the discovery and development of additional platinum-based anticancer drugs. Platinum drug development has proceeded in two broad directions concomitant with the two main limitations of cisplatin itself: namely its severe side-effects (especially on the kidneys, gastrointestinal tract and peripheral nerves) and its poor activity against some common tumours (e.g. colorectal and non-small-cell lung cancers) combined with its inability to confer lasting remissions in responding tumour types (especially ovarian) due to the emergence of drug resistance.
Preview
Unable to display preview. Download preview PDF.
References
Aamdal, S., Piccart, M., Wanders, J., Rastogi, R. B., Schwartsman, G., Franklin, H. R. and Kaye, S. B. (1991). Phase II study of zeniplatin (CL286,558) [2,2bis(aminomethyl)-1,3-propanediol-N,N’] [1, 1-cyclobutanedicarboxylato(2-)O,O’]platinum(II) in patients with advanced melanoma. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 167
Advanced Ovarian Cancer Trialists Group (1991). Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br. Med. J., 303, 884–893
Alvarez, M., Rixe, O., Reed, E. and Fojo, A. T. (1992). Characterization of protein changes in cisplatin (CP) resistant A2780 human ovarian carcinoma and KB cell lines. Proc. Am. Assoc. Cancer Res., 33, A3224
Anderson, W. K., Quagliato, D. A., Haugwitz, R. D., Narayanan, V. L. and Wolpert-DeFilippes, M. K. (1986). Synthesis, physical properties and antitumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat. Rep., 70, 997–1002
Andrews, P. A. and Albright, K. D. (1992). Mitochondrial defects in cisdiamminedichloro platinum(II)-resistant human ovarian carcinoma cells. Cancer Res., 52, 1895–1901
Andrews, P. A. and Howell, S. B. (1990). Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35–43
Andrews, P. A., Jones, J. A., Varki, N. M. and Howell, S. B. (1990). Rapid emergence of acquired cis-diamminedichloroplatinum (II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun., 2, 93–100
Andrews, P. A., Mann, S. C., Huynh, H. H. and Albright, K. D. (1991). Role of the Na+, K+-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res., 51, 3677–3681
Andrews, P. A., Murphy, M. P. and Howell, S. B. (1987). Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Che-mother. Pharmacol., 19, 149–154
Andrews, P. A., Murphy, M. P. and Howell, S. B. (1989). Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells. Eur. J. Cancer Clin. Oncol., 25, 619–625
Andrews, P. A., Velury, S., Mann, S. C. and Howell, S. B. (1988). cisdiamminedichloro platinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48, 68–73
Ariyoshi, Y. and Ota, K., (1989). Preclinical and clinical evaluation of toxicities and antitumour activities of cisplatin analogues. Jpn J. Cancer Chemother., 16, 1379–1385
Ariyoshi, Y., Ota, K., Wakui, A., Majima, H., Niitani, H., Ogawa, M., Inuyama, Y., Yoshida, O., Taguchi, T., Kimura, I. and Kato, T. (1988). Phase I study of [glycolato-O,O’] diammine platinum (II) (254-S). Proc. Am. Soc. Clin. Oncol., 7, A222.
Bakka, A., Endresen, L., Johnsen, A. B. S., Edminson, P. D. and Rugstad, H. E. (1981). Resistance against cis-diamminedichloro platinum in cultured cells with a high content of metallothionein. Toxicol. Appl. Pharmacol., 61, 215–226
Basu, A., Kozikowski, A. P., Sato, K. and Lazo, J. S. (1991). Cellular sensitization to cis-diamminedichloro platinum (II) by novel analogues of the protein kinase C activator lyngbyatoxin A. Cancer Res., 51, 2511–2514
Basu, A. and Lazo, J. S. (1991). Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloro platinum (II) resistance by v-mos. Cancer Res., 51, 893–896
Basu, A. and Lazo, J. S. (1992). Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res., 52, 3119–3124
Basu, A., Teicher, B. A. and Lazo, J. S. (1990). Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloro platinum (II). J. Biol. Chem., 265, 8451–8457
Bedford, P., Fichtinger-Schepman, M. J., Shellard, S. A., Walker, M. C., Masters, J. R. W. and Hill, B. T. (1988). Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res., 48, 3019–3024
Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C. and Ozols, R. F. (1987). Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian carcinoma cell line and its use in evaluation of platinum analogs. Cancer Res., 47, 414–418
Bernal, S. D., Speak, J. A., Boeheim, K., Dreyfuss, A. I., Wright, J. E., Teicher, B. A., Rosowsky, A., Tsao, S. W. and Wong, Y. C. (1990). Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol. Cell. Biochem., 95, 61–70
Bitha, P., Carvajal, S. G., Citarella, R. V., Delos Santos, E. F., Durr, F. E., Hlavka, J. J., Lang, S. A., Lindsay, H. L., Thomas, J. P., Wallace, R. E. and Lin, Y. (1989). Water-soluble third generation antitumor platinum complexes, [2,2-bis(aminomethyl)-1,3-propanediol-N,N’][1,1-cyclobutanedicarboxylato (2-)O,O’]platinum(II) and [1,1-cyclobutanedicarboxylato (2-)-O,O’][tetrahydro4H-pyran-4,4-dimethanamine-N,N’]platinum(II). J. Med. Chem., 32, 2015–2020
Boughattas, N. A., Levi, F., Fournier, C., Lemaigre, G., Roulon, A., Hecquet, B., Mathé, G. and Reinberg, A. (1989). Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum (II) in mice. Cancer Res., 49, 3362–3368
Bungo, M., Fujiwara, Y., Kasahara, K., Nakagawa, K., Ohe, Y., Sasaki, Y., Irino, S. and Saijo, N. (1990). Decreased accumulation as a mechanism of resistance to cis-diamminedichloro platinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res., 50, 2549–2553
Bunn, P., Canetta, R., Ozols, R. and Rozencweig, M. (Eds) (1990). Carboplatin; Current Perspectives and Future Directions. W. B. Saunders, Philadelphia
Burchenal, J. H., Kalaher, K., Dew, K. and Lokys, L. (1979). Rationale for development of platinum analogs. Cancer Treat. Rep., 63, 1493–1498
Carfagna, P. F., Poma, A., Wyrick, S. D., Holbrook, D. J. and Chaney, S. G. (1991). Comparisons of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fisher 344 rats at therapeutic and toxic doses. Cancer Chemother. Pharmacol., 27, 335–341
Canetta, R., Rozencweig, M., Wittes, R. E. and Schacter, L. P. (1990). Platinum coordination complexes in cancer chemotherapy: an historical perspective. In Cancer Chemotherapy: Challenges for the Future, Vol. 5. Excerpta Medica, Tokyo, pp. 318–323
Caussanell, J. P., Levi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B. and Mathé, G. (1990). Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl Cancer Inst., 82, 1046–1050
Ceulemans, F., Duprez, P., Vindevogel, A., Tueni, E., Piccart, M., Kerger, J., Rastogi, R. and de Halleux, F. (1991). Enloplatin (CL287,110): Phase I study in patients with advanced solid tumours. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 168
Chao, C. C.-K., Lee, Y. L., Cheng, P.-W. and Lin-Chao, S. (1991). Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diamminedichloroplatinum (II). Cancer Res., 51, 601–605
Christen, R. C., Horn, D. K., Porter, D. C., Andrews, P. A., MacLeod, C. L., Hafstrom, L. and Howell, S. B. (1990). Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest., 86, 1632–1640
Christian, M. C., Kohn, E., Sarosy, G., Link, C., Davis, P., Adamo, D., Weiss, R. B., Brewster, L., Lombardo, F. and Reed, E. (1992). Phase I and pharmacologic study of ormaplatin (OP)/tetraplatin. Proc. Am. Soc. Clin. Oncol., 11, abs. 291
Connors, T. A., Jones, M., Ross, W. C. J., Braddock, P. D., Khokhar, A. R. and Tobe, M. L. (1972). New platinum complexes with anti-tumour activity. Chem.biol. Interact., 5, 415–424
Dabholkar, M., Bostick-Bruton, F. and Reed, E. (1992). ERCC1 and ERCC2 expression in fresh human tumor tissues. Proc. Am. Assoc. Cancer Res., 33, A1417
De Graeff, A., Slebos, R. J. C. and Rodenhuis, S. (1988). Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Che-mother. Pharmacol., 22, 325–332
Dempke, W. C. M., Shellard, S. A., Fichtinger-Schepman, A. M. J. and Hill, B. T. (1991). Lack of significant modulation of the formation and removal of platinum—DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro. Carcinogenesis, 12, 525–528
Dodion, P. F., de Valeriola, D., Crepeigne, N., Kantrowitz, J. D., Piccart, M., Wery, F., Kerger, J., Egorin, M. J., Forrest, A., Bachur, N. R., Alaerts, P., Carver, A., Rastogi, R., Hammershaimb, L. and Saletan, S. (1991). Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann. Oncol., 2, 589–596
Dougherty, W. J., Tiner, J. D., Tham, P. and Irwin, M. (1991). Preclinical toxicology of enloplatin. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 297
Eastman, A. (1990). Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor), 2, 275–280
Eastman, A. and Schulte, N. (1988). Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloro platinum (II). Biochemistry, 27, 4730–4734
Eisenhauer, E., Swerton, K., Sturgeon, J., Fine, S., O’Reilly, S. and Canetta, R. (1990). Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. In Bunn, P., Canetta, R., Ozols, R. and Rozencweig, M. (Eds), Carboplatin; Current Perspectives and Future Directions. W. B. Saunders, Philadelphia, pp. 133–140
Enns, R. E. and Howell, S. B. (1991). Isolation of a gene associated with resistance to cisplatin. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy. Plenum Press, New York, pp. 213–219
Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L. and Marty, M. (1990). Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25, 299–303
Farrell, N., Kelland, L. R., Roberts, J. D. and Van Beusichem, M. (1992). Activation of the trans geometry in platinum antitumor complexes: A survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res., 52, 5065–5072
Farrell, N., Qu, Y., Feng, L. and Van Houten, B. (1990b). Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. Biochemistry, 29, 9522–9531
Farrell, N., Qu, Y. and Hacker, M. P. (1990a). Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J. Med. Chem., 33, 2179–2184
Fiebig, H. H., Berger, D. P., Mross, K., Queiber, W., Aulenbacher, P. and Hilgard, P. (1992). Lobaplat (D19466): Preclinical drug profile and results of the phase I study. Ann. Oncol., 3 (Suppl. 1), A338
Fram, R. J., Woda, B. A., Wilson, J. M. and Robichaud, N. (1990). Characterization of acquired resistance to cis-diamminedichloro platinum (II) in BE human colon carcinoma cells. Cancer Res., 50, 72–77
Freise, J., Mueller, W. H., Magerstedt, P. and Schmoll, H. J. (1982). Pharmacokinetics of liposome-encapsulated cis-platin in rats. Arch. Int. Pharmacodyn. Ther., 258, 180–192
Fujiwara, Y., Sugimoto, Y., Kasahara, K., Bungo, M., Yamakido, Y., Tew, K. D. and Saijo, N. (1990). Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J. Cancer Res., 81, 527–535
Fukuda, M., Shinkai, T., Eguchi, K., Sasaki, Y., Tamura, T., Ohe-Y., Kojima, A., Oshita, F., Hara, K. and Saijo, N. (1990). Phase II study of (glycolate-O,O’) diammineplatinum(II), a novel platinum complex, in the treatment of non-smallcell lung cancer. Cancer Chemother. Pharmacol., 26, 393–396
Fukuoka, M., Niitani, H., Hasegawa, K., Majima, H., Hino, M., Furue, H., Tsukagoshi, S., Fujita, H., Ohta, K., Furuse, K., Kimura, I. and Katoh, T. (1989). Phase I study of new platinum compound, NK121. Proc. Am. Soc. Clin. Oncol., 8, A240
Galeano, A., Berger, M. R. and Keppler, B. K. (1992). Activity of two platinum-linked phosphonic acids against autochthonous rat colorectal cancer as well as in two human colon-cancer cell lines. Cancer Chemother. Pharmacol., 30, 131–138
Giandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Harrap, K. R., Goddard, P. M., Kelland, L. R. and Morgan, S. E. (1991). Synthesis and reactions of a new class of orally active Pt (IV) antitumor complexes. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Complexes in Cancer Chemotherapy. Plenum Press, New York, pp. 93–100
Gibbons, G. R., Wyrick, S. and Chaney, S. G. (1989). Rapid reduction of tetrachloro(D,L-trans)1,2-diamincyclohexaneplatinum(IV) (tetraplafin) in RPMI 1640 tissue culture medium. Cancer Res., 49, 1402–1407
Gibson, D., Gean, K.-F., Ben-Shoshan, R., Ramu, A., Ringel, I. and Katzhendler, J. (1991). Preparation, characterization, and anticancer activity of a series of cis-PtC12 complexes linked to anthraquinone intercalators. J. Med. Chem., 34, 414–420
Gietema, J. A., de Vries, E. G. E., Sleijfer, D. Th., Aulenbacher, P., Williemse, P. H. B. and Mulder, N. H. (1992). Clinical studies with 1,2-diamminomethylcyclobutane-platinum(II)-lactate (D19466; Lobaplatin). Ann. Oncol., 3 (Suppl. 1), A337
Goddard, P. M., Valenti, M. R. and Harrap, K. R. (1991). The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: A cautionary note. Ann. Oncol., 2, 535–540
Gore, M., Fryatt, I., Wiltshaw, E., Dawson, T., Robinson, B. and Calvert, A. (1989). Cisplatin/carboplatin cross-resistance in ovarian cancer. Br. J. Cancer, 60, 767–769
Grunicke, H. H., Hofmann, J., Maly, K., Oberhuber, H., Uberall, F., Egle, A. and Demuth, L. (1991). Enhancement of the antiproliferative effect of cisdiamminedichloro platinum (II) and other antitumor agents by inhibitors of enzymes involved in growth factor signal-transduction. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 161–172
Hamers, F. P. T., Gerritsen van der Hoop, R., Steerenberg, P. A., Neijt, J. P. and Gispen, W. H. (1991). Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol. Appl. Pharmacol., 111, 514–522
Harrap, K. R. (1983). Platinum analogues: criteria for selection. In Muggia, F. M. (Ed.), Cancer Chemotherapy 1. Martinus Nijhoff, The Hague, pp. 171–217
Harrap, K. R., Jones, M., Siracky, J., Pollard, L. and Kelland, L. R. (1990). The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann. Oncol., 1, 65–76
Hanap, K. R., Kelland, L. R., Jones, M., Goddard, P. M., On, R. M., Morgan, S. E., Murrer, B. A., Abrams, M. J. and Giandomenico, C. M. (1991a). Platinum coordination complexes which circumvent cisplatin resistance. Adv. Enzyme Regulation, 31, 31–43
Hanap, K. R., Murrer, B. A., Giandomenico, C., Morgan, S. E., Kelland, L. R., Jones, M., Goddard, P. M. and Schurig, J. (1991b). Ammine/amine platinum IV dicarboxylates: a novel class of complexes which circumvent intrinsic cisplatin resistance. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 391–399
Hecquet, B., Fournier, C., Boughattas, N. and Levi, F. (1992). Pharmacokinetics and tissue distribution of IOHP in mice with comparison to cisplatin and carboplatin. Ann. Oncol., 3 (Suppl. 1), A530
Hill, B. T., Shellard, S. A., Whelan, R. D. H., Pera, M. F., Harstrick, A. and Fichtinger-Schepman, A. M. J. (1992). Deficient removal of the major platinum-DNA intrastrand crosslinks in the sequences pGpG and pApG appears characteristic of testicular teratoma cell lines derived from tumours from untreated patients and may account for their sensitivity to cisplatin. Proc. Am. Soc. Clin. Oncol., 11, A221
Hills, C. A., Kelland, L. R., Abel, G., Siracky, J., Wilson, A. P. and Harrap, K. R. (1989). Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59, 527–534
Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Uberall, F. and Grunicke, H. H. (1988). Enhancement of the antiproliferative effect of cisdiamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42, 382–388
Hofmann, J., Ueberall, F., Posch, L., Maly, K., Herrmann, D. B. J. and Grunicke, H. (1989). Synergistic enhancement of the antiproliferative activity of cis-diamminedichloro platinum(II) by the ether lipid analogue BM41440, an inhibitor of protein kinase C. Lipids, 24, 312–317
Hollis, S. L., Amundsen, A. R. and Stern, E. W. (1989). Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]. J. Med. Chem., 32, 128–136
Hollis, S. L., Sundquist, W. I., Burstyn, J. N., Heiger-Bernays, W. J., Bellon, S. F., Ahmed, K. J., Amundsen, A. R., Stern, E. W. and Lippard, S. J. (1991). Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents. Cancer Res., 51, 1866–1875
Hosking, L. K., Whelan, D. H., Shellard, S. A., Bedford, P. and Hill, B. T. (1990). An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines. Biochem. Pharmacol., 40, 1833–1842
Hospers, G. A. P., Mulder, N. H., de Jong, B., de Ley, L., Uges, D. R. A., Fichtinger-Schepman, A. M. J., Scheper, R. J. and de Vries, E. G. E. (1988). Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloro platinum (II) in vitro. Cancer Res., 48, 6803–6807
Howell, S. B., Isonishi, S., Christen, R. C., Andrews, P. A., Mann, S. C. and Horn, D. (1991). Signal transduction pathway regulation of DDP sensitivity. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 173–179
Hudes, G. R., O’Dwyer, P. J., Walczak, J., LaCreta, F. P., Cohen, I., Kowal, C., Boyd, R. A. and Whitfield, L. R. (1991). Phase I/pharmacokinetic study of the new platinum compound CI-973 on a 5-day schedule. Proc. Am. Assoc. Cancer Res., 32, A1190
Hydes, P. C. and Russell, M. J. H. (1988). Advances in platinum cancer chemotherapy: Advances in the design of cisplatin analogues. Cancer and Metastasis Reviews, 7, 67–89
Isonishi, S., Andrews, P. A. and Howell, S. B. (1990). Increased sensitivity to cis-diamminedichloro platinum (II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J. Biol. Chem., 265, 3623–3627
Isonishi, S., Hom, D. K., Thiebaut, F. B., Mann, S. C., Andrews, P. A., Basu, A., Lazo, J. S., Eastman, A. and Howell, S. B. (1991). Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res., 51, 5903–5909
Jiao, L., Funato, T., Wang, W., Tone, T., Kashani-Sabet, M. and Scanlon, K. J. (1991). The role of the c-fos oncogene in cisplatin resistance. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 303–313
Jones, A. L., McKeage, M., Davies, C., Holburn, J., Ashley, S. E., Rastogi, R., Townsend, H. and Smith, I. E. (1992a). Phase II study of zeniplatin in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. (in press)
Jones, J. C., Zhen, W., Reed, E., Parker, R. J., Sancar, A. and Bohr, V. A. (1991). Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand crosslinks in Chinese hamster ovary cells. J. Biol. Chem., 266, 7101–7107
Jones, M., Siracky, J., Kelland, L. R. and Hanap, K. R. (1992b). Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br. J. Cancer, 67, 27–29
Kameyama, Y., Okazaki, N., Nakagawa, M., Koshida, H., Nakamura M. and Gemba, M. (1990). Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney slices. Toxicol. Len., 52, 15–24
Kanzawa, F., Matsushima, Y., Nakagawa, K., Takahashi, H., Sasaki, Y. and Saijo, N. (1988) Antitumour activity of a new platinum compound (glycolate-) diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumour clonigenic assay system. Anticancer Res., 8, 323–328
Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., Matsuda, T. and Saijo, N. (1991). Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 51, 3237–3242
Kashani-Sabet, M., Wang, W. and Scanlon, K. J. (1990). Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J. Biol. Chem., 265, 11285–11288
Kawai, K., Kamatani, N., Georges, E. and Ling, V. (1990). Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloro platinum (II). J. Biol. Chem., 265, 13137–13142
Kawai, K., Kamatani, N., Kuroshima, S., Nobori, T., Nishioka, K., Kamiya, H., Sakurai, M. and Mikanagi, K. (1987). Cross-resistance to ouabain in a murine leukemia cell variant selected for cis-diammine dichloro platinum(II) resistance. Cancer Lett., 35, 147–152
Kelland, L. R., Jones, M., Abel, G. and Harrap, K. R. (1992a). Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother. Pharmacol., 30, 43–50
Kelland, L. R., Jones, M., Goddard, P. M., Murrer, B. A. and Hanap, K. R. (1992b). Preclinical antitumor activity of Bis-acetato-ammine dichloro (cyclohexylamine) platinum (IV) (JM216): An orally active platinum drug. Proc. Am. Assoc. Cancer Res., 33, A3342
Kelland, L. R., Mistry, P., Abel, G., Freidlos, F., Loh, S. Y., Roberts, J. J. and Harrap, K. R. (1992c). Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular non-seminomatous germ cell line. Cancer Res., 52, 1710–1716
Kelland, L. R., Mistry, P., Abel, G., Loh, S. Y., O’Neill, C. F., Murrer, B. A. and Hanap, K. R. (1992d). Mechanism-related circumvention of cis-diamminedichloro platinum (II) acquired resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum (IV) dicarboxylates. Cancer Res., 52, 3857–3864
Kelland, L. R., Murrer, B. A., Abel, G., Giandomenico, C. M., Mistry, P. and Hanap, K. R. (1992e). Ammine/amine platinum (N) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res., 52, 822–828
Kelland, L. R., Murrer, B. A., Abel, G. and Hanap, K. R. (1991). Structure-activity relationships in a series of novel platinum (II) and platinum (IV) ammine/amine complexes evaluated against a panel of human ovarian carcinoma cell lines. J. Cell Pharmacol., 2, 331–342
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H. and Lazo, J. S. (1988). Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241, 1813–1815
Kelley, S. L. and Rozencweig, M. (1989). Resistance to platinum compounds: mechanisms and beyond. Eur. J. Cancer Clin. Oncol., 25, 1135–1140
Kelsen, D. P., Scher, H., Burchenal, J. (1984). In Hacker, M. P., Douple, E. B. and Krakoff, I. H. (Eds), Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston, pp. 311–320
Kerr, D. J., Khan, M., Plumb, J. A., Freshney, R. I. and Spandidos, D. A. (1991). The effect of H-ras and c-myc oncogene transfection on the response of epithelial cells to cisplatin and growth factors. Proceedings of the Sixth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, p. 96
Khokhar, A. R., Al-Baker, S., Krakoff, I. H. and Perez-Soler, R. (1989). Toxicity and antitumour activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. Cancer Chemother. Pharmacol., 23, 219–224
Khokhar, A. R., Al-Baker, S., Krakoff, I. H. and Perez-Soler, R. (1992). Chemical and biological properties of highly lipophilic cisplatin analogues entrapped in liposomes. Proc. Am. Assoc. Cancer Res., 33, A3227
Kidani, Y., Inagaki, K., Iigo, M., Hoshi, A. and Kazuo, K. (1978). Antitumour activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form. J. Med. Chem., 21 (12), 1315–1318
Kikuchi, Y., Iwano, I., Miyauchi, M., Kita, T., Sugita, M., Tenjin, Y. and Nagata, (1990a). Possible mechanisms of resistance to cis-diamminedichloroplatinum (II) of human ovarian cancer cells. Jpn J. Cancer Res., 81, 701–706
Kikuchi, Y., Iwano, I., Miyauchi, M., Sasa, H., Nagata, I. and Kuki, E. (1990b). Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian cancer cells. Gynecol. Oncol., 39, 199–203
Kimura, E., Enns, R. E., Arboleda, M. J., Slamon, D. J. and Howell, S. B. (1992). Correlation of survival with mRNA expression of 60 kD heat shock protein (HSP-60) in ovarian cancer patients. Proc. Am. Soc. Clin. Oncol., 11, A225
Knebel, N. G. and Von Angerer, E. (1991). 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum (II): complexes with a selective action on estrogen receptor positive mammary tumors. J. Med. Chem., 34, 2145–2152
Knox, R. J., Friedlos, F., Lydall, D. A. and Roberts, J. J. (1986). Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminedichloro platinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res., 46, 1972–1979
Kraker, A. J. and Moore, C. W. (1988a). Accumulation of cis-diamminedichloro platinum (II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res., 48, 9–13
Kraker, A. J. and Moore, C. W. (1988b). Elevated DNA polymerase beta activity in a cis-diamminedichloro platinum (II) resistant P388 murine leukemia cell line. Cancer Lett., 38, 307–314
Kramer, B. S., Birch, R., Greco, A., Prestridge, K., DeSimone, P. and Omura, G. (1988). Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer. Am. J. Clin. Oncol., 11, 643 645
Kreisman, H., Ginsberg, S., Propert, K. J., Richards, F., Graziano, S. and Green, M. (1987). Carboplatin or iproplatin in advanced non-small cell lung cancer: A Cancer and Leukaemia Group B study. Cancer Treat. Rep., 71, 1049–1052
Kuppen, P. J. K., Schuitemaker, H., Veer, L. J., Bruijn, E. A., Oosterom, A. T. and Schrier, P. I. (1988). cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res., 48, 3355–3359
Lai, G. M., Ozols, R. F., Smyth, J. F., Young, R. C. and Hamilton, T. C. (1988). Enhanced DNA repair to cisplatin in human ovarian cancer. Biochem. Pharma-col., 37, 4597–4600
Lai, G. M., Ozols, R. F., Young, R. C. and Hamilton, T. C. (1989). Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Natl Cancer Inst., 81, 535–539
Lévi, F., Misset, J-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J-P., Kunstlinger, F., Lecouturier, S., Descorps-Declére, A., Jasmin, C., Bismuth, H. and Reinberg, A. (1992). A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer, 69, 893–900
Lewis, A. D., Hayes, J. D. and Wolf, C. R. (1988). Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis, 9, 1283–1287
Loh, S. Y., Mistry, P., Kelland, L. R., Abel, G., and Harrap, K. R. (1992). Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br. J. Cancer, 66, 1109–1115
Los, G., Mutsaers, P. H., Ruevekamp, M., McVie, J. G. (1990). The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett., 51, 109–117
McGuire III, W. P., Arseneau, J., Blessing, J. A., DiSaia, P. J., Hatch. K. D., Given, F. T., Teng, N. N. H. and Creasman, W. T. (1989). A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: A Gynecology Oncology Group study. J. Clin. Oncol., 7, 1462–1468
McKeage, M. J., Morgan, S. E., Boxall, F. E., Hard, G. C., Murrer, B., Judson, I. and Harrap, K. (1992). Acute toxicology of orally administered bis-acetatoammine dichloro (cyclohexylamine) platinum(IV) (JM216) in rodents. Proc. Am. Assoc. Cancer Res., 33, A3197
Majima, H. (1991). Clinical studies with cisplatin analogues, 254-S, DWA 2114R and NK121. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 345–355
Mangioni, C., Bolis, G., Pecorelli, S., Bragman, K., Epis, A., Favalli, G., Gambino, A., Landoni, F., Presti, M., Tom, W., Vassena, L., Zanaboni, F. and Marsoni, S. (1989). Randomised trial in ovarian cancer comparing cisplatin and carboplatin. J. Natl Cancer Inst., 81, 1464–1468
Mann, S. C., Aniirews, P. A. and Howell, S. B. (1991). Modulation of cisdiamminedichloro platinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J. Cancer, 48, 866–872
Masuda, H., Ozols, R. F., Lai, G-M., Fojo, A., Rothenberg, M. and Hamilton, T. C. (1988). Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res., 48, 5713–5716
Masuda, H., Tanaka, T., Matsuda, H. and Kusaba, I. (1990). Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cisdiamminedichloroplatinum (II). Cancer Res., 50, 1863–1866
Mathé, G., Kidani, Y., Noji, M., Maral, R., Bourut, C. and Chenu, E. (1985). Antitumor activity of 1-OHP in mice. Cancer Lett., 27, 135–143
Mathé, G., Kidani, Y., Segiguchi, M., Eriguchi, M., Fredj, G., Peytavin, G., Misset, J. L., Brienza, S., De Vassals, F., Chenu, E. and Bourut, C. (1989). Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43, 237–250
Mathé, G., Kidani, Y., Triana, K., Brienza, S., Ribaud, P., Goldschmidt, E., Ecstein, E., Despax, R., Musset, M. and Misset, J. L. (1986). A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP). Biomed. Pharmacother., 40, 372–376
Matsumoto, T., Endoh, K., Akamatsu, K., Kamisango, K., Mitsui, H., Koizumi, K., Morikawa, K., Koizumi, M. and Matsuno, T. (1991). Comparison of the anti-tumour effects and nephrotoxicity-inducing activities of two new platinum complexes (—)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum(II) monohydrate, and its enantiomeric isomer. Br. J. Cancer, 64, 41–46
Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Meersma, G. J. and De-Vries, E. G. (1991). Role of GSH in the efficacy of 7 platinum (Pt) compounds in 2 cisplatin (CDDP)-resistant human cell lines. Proc. Am. Assoc. Cancer Res., 32, A2427
Mistry, P. and Harrap, K. R. (1991). Historical aspects of glutathione and cancer chemotherapy. Pharmacol. Ther., 49, 125–132
Mistry, P., Kelland, L. R., Abel, G., Sidhar, S. and Hanap, K. R. (1991). The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64, 215–220
Mistry, P., Kelland, L. R., Loh, S. Y., Abel, G., Murrer, B. A. and Harrap, K. R. (1992). Cellular accumulation and cytotoxicity of platinum drugs in five human ovarian carcinoma cell lines. Cancer Res., 52, 6188–6193
Morikage, T., Bungo, M., Inomata, M., Yoshida, M., Ohmori, T., Fujiwara, Y., Nishio, K. and Saijo, N. (1991). Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line. Jpn J. Cancer Res., 82, 747–751
Muggia, F. M., Wolpert-DeFilippes, M. K., Ribaud, P. and Mathé, G. (1980). Clinical results with cisplatin analogs. In Prestayko, A. W., Crooke, S. T. and Carter, S. K. (Eds), Cisplatin: Current Status and New Developments. Academic Press, New York, pp. 517–527
Murphy, D., McGown, A. T., Crowther, D., Mander, A. and Fox, B. W. (1991). Metallothionein levels in ovarian tumours before and after chemotherapy. Br. J. Cancer, 63, 711–714
Nakagawa, K., Yokota, J., Wada, M., Sasaki, Y., Fujiwara, Y., Sakai, M., Muramatsu, M., Terasaki, T., Tsunokawa, Y., Terada, M. and Saijo, N. (1988). Levels of glutathione S transferase IImRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J. Cancer Res. (Gann), 79, 301–304
Nicholson, M. C., On, R. M., O’Neill, C. F. and Hanap, K. R. (1992). The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Neoplasma, 39 (3), 189–195
Niimi, S, Nakagawa, K., Yokota, J., Tsunokawa, Y., Nishio, K., Terashima, Y., Shibuya, M., Terada, M. and Saijo, N. (1991). Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br. J. Cancer, 63, 237–241
Nishizuka, Y. (1988). The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature, 334, 661–665
Olver, I., Green, M., Peters, W., Zimet, A., Toner, G., Bishop, J., Ketelbey, W., Astogi, R. and Birkhofer, M. (1992). A pilot phase II study of zeniplatin in metastatic melanoma. Ann. Oncol., 3 (Suppl. 1), A345
O’Neill, C. F., Orr, R. M., Kelland, L. R. and Hanap, K. R. (1992). Formation and removal of platinum/DNA adducts in human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Proc. Am. Assoc. Cancer Res., 33, A3196
O’Rourke, T., Rodriguez, G., Eckardt, J., Kuhn, J., Bums, H., Hardy, J., Weiss, G. and Von Hoff, D. (1992). Phase I clinical trial ormaplatin (NSC363812) given on a daily ×5, every 28 day schedule. Proc. Am. Assoc. Cancer Res., 33, A3215
Orr, R. M., Barnard, C. F. J., Murrer, B. A., O’Neill, C. F., Nicolson, M. C., Balazova, E. and Harrap, K. R. (1992). Evaluation of novel platinum (II) and platinum (IV) ammine/amine complexes in L1210 murine leukaemia cell lines sensitive and resistant to cisplatin and tetraplatin. J. Cell Pharmacol. (in press)
Ota, K., Miyake, H., Inuyama, I., Niitani, H., Kimura, I., Ogawa, M., Yoshida, M., Taguchi, T., Wakui, A., Yoshida, O., Kato, T., Noda, K., Aso, Y., Taguchi, Y. and Sakuma, A. (1992). Clinical evaluation of cis-diammine(glycolato)platinum(II), 254-S. A new anticancer platinum complex. Ann. Oncol., 3 (Suppl. 1), A340
Ozols, R. F. (1991). Ovarian cancer: new clinical approaches. Cancer Treat. Rev., 18 ( Suppl. A), 77–83
Parker, R. J., Eastman, A., Bostick-Bruton, F. and Reed, E. (1991). Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest., 87, 772–777
Pendyala, L., Creaven, P. J., Shah, G., Molnar, M. V. and Grandjean, E. M. D. (1991). In vitro cytotoxicity studies of oxaliplatin in human tumor cell lines. Proc. Am. Assoc. Cancer Res., 32, A2441
Pera, M. F., Friedlos, F., Mills, J. and Roberts, J. J. (1987). Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloro platinum (II) on DNA. Cancer Res., 47, 6810–6813
Perez-Soler, R., Khokhar, A. R. and Lopez-Berestein, G. (1987). Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) encapsulated in multilamellar vesicles. Cancer Res., 47, 6462–6466
Perez-Soler, R., Lautersztain, J., Stephens, L. C., Wright, K. and Khokhar, A. R. (1989). Preclinical toxicity and pharmacology of liposome-entrapped cisbisneodecanoato-trans-R,R-1,2-diaminocyclohexane Platinum (II). Cancer Che-mother. Pharmacol., 24, 1–8
Perez-Soler, R., Lopez-Berestein, G., Lautersztain, J., Al-Baker, S., Francis, K., Macias-Kiger, D., Raber, M. N. and Khokhar, A. R. (1990). Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R1,2-diaminocyclohexane platinum (II). Cancer Res., 50, 4254–4259
Perez-Soler, R., Siddik, Z. H., Vadiei, K., Krakoff, I. H. and Khokhar, A. R. (1991). Pharmacologic studies with new liposome-entrapped cisplatin derivatives. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 377–389
Piccart, M., Kerger, J., Tueni, E., van der Schueren, E., Kennes, C., Bartholomeus, S., Vantongelen, K., Rastogi, R. and Birkhofer, M. (1991). Phase II trial of zeniplatin (CL 286,558; ZNP) as second-line treatment in metastatic breast cancer (MBC). Proc. Am. Assoc. Cancer Res., 32, Al222
Rhodes, T. and Twentyman, P. R. (1992). A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug resistant cell lines. Br. J. Cancer, 65, 684–690
Roberts, J. D., Van Houten, B., Qu, Y. and Farrell, N. P. (1989). Interaction of novel bis(platinum) complexes with DNA. Nucleic Acids Res., 17, 9719–9733
Roberts, J. J., Knox, R. J., Friedlos, F. and Lydall, D. A. (1986). DNA as the target for the cytotoxic and anti-tumour action of platinum co-ordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In McBrien, D. C. H. and Slater, T. F. (Eds), Biochemical Mechanisms of Platinum Antitumour Drugs. IRL Press, Oxford, pp. 29–64
Rosenberg, B. (1985). Fundamental studies with cisplatin. Cancer, 55, 2303–2316
Rubin, E., Kharbanda, S., Gunji, H., Weichselbaum, R. and Kufe, D. (1992). cis-Diamminedichloro platinum (II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res., 52, 878–882
Saburi, Y., Nakagawa, M., Ono, M., Sakai, M., Muramatsu, M., Kohno, K. and Kuwano, M. (1989). Increased expression of glutathione S-transferase gene in cis-diamminedichloro platinum(II)-resistant variants of a Chinese hamster ovary cell line. Cancer Res., 49, 7020–7025
Sasaki, Y., Amano, T., Morita, M., Shinkai, T, Eguchi, K., Tamura, T., Ohe, Y., Kojima, A. and Saijo, N. (1991). Phase I study and pharmacological analysis of cis-diammine(glycolato) platinum(II) (254-S; NSC 375101d) administered by 5-day continuous intravenous infusion. Cancer Res., 51, 1472–1477
Sasaki, Y., Tamura, T., Eguchi, K., Shinkai, T., Fujiwara, Y., Fukuda, M., Ohe, Y., Bungo, M., Horichi, N., Niimi, S., Minato, K., Nakagawa, K. and Saijo, N. (1989). Pharmacokinetics of [glycolato-O,O’]-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Che-mother. Pharmacol., 23, 243–246
Scanlon, K. J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J. J. and Kashani-Sabet, M. (1991). Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl Acad. Sci. USA, 88, 10591–10595
Scanlon, K. J., Kashani-Sabet, M., Miyachi, H., Sowers, L. and Rossi, J. (1989a). Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients. Anticancer Res., 9, 1301–1312
Scanlon, K. J., Kashani-Sabet, M. and Sowers, L. C. (1989b). Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. Cancer Commun., 1, 269–275
Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, Jr A. J., Ozols, R. F., Fojo, A. T. and Hamilton, T. C. (1990). Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer, 45, 416–422
Schilder, R. J., LaCreta, F. P., Perez, R. P., Nash, S., Hamilton, T. C., Goldstein, L. J., Young, R. C., Ozols, R. F. and O’Dwyer, P. J. (1992). Phase U pharmacokinetic study of ormaplatin (tetraplatin, NSC363812). Proc. Am. Assoc. Cancer Res., 33, A3211
Sekiguchi, M., Eriguchi, M., Shiroko, Y., Akiyama, N. and Mikamo, S. (1992). Chemosensitivity screening in vitro of various cultured human cancer cell lines to a new platinum complex. l-OHP: Oxalato(trans-l-1,2-diaminocyclohexane)platinum(II). Ann. Oncol., 3 (Suppl. 1), A194
Shiratori, O., Kasi, H., Uchida, N., Takeda, Y., Totano, T. and Sato, K. (1985). Antitumour activity of 254-S, a platinum complex, in rodents. In Shigama, J. (Ed.), Recent Advances in Chemotherapy: Anticancer Section 1. University of Tokyo Press, Tokyo, pp. 635–636
Silvestro, L., Anal, H., Sommer, F., Trincal, G. and Tapiero, H. (1990). Comparative effects of a new platinum analog (trans-l-diamine-cyclohexane oxalatoplatinum: l’OHP) with CDDP on various cells: correlation with intracellular accumulation. Anticancer Res., 10 (5B), 1376
Sklar, M. D. (1988). Increased resistance to cis-diamminedichloro platinum (II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res., 48, 793–797
Sklar, M. D. and Prochownik, E. V. (1991). Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res., 51, 2118–2123
Tamura, K., Makino, S. and Araki, Y. (1990). A phase I study of a new cisplatin derivative for haematological malignancies. Cancer, 66, 2059–2063
Tashiro, T., Kawada, Y., Sakurai, Y. and Kidani, Y. (1989). Antitumour activity of a new platinum complex oxalato [trans-1,2-diaminocyclohexane platinum(II): new experimental data. Biomed. Pharmacother., 43, 251–260
Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. M., Peeffer, R., Crawford, J. W. and Frei, E. III (1990a). Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 245, 1457–1461
Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V., Rosbe, K. W., Brann, T. W., Korbut, T. T. and Frei, E. III (1990b). Characteristics of five human tumor cell lines and sublines resistant to cisdiamminedichloro platinum (II). Int. J. Cancer, 47, 252–260
Teicher, B. A., Holden, S. A., Kelley, M. J., Shea, T. C., Cucchi, C. A., Rosowsky, A., Henner, W. D. and Frei, E. III (1987). Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloro platinum (II). Cancer Res., 47, 388–393
Theriault, R., Esparza, L., Raber, M., Newman, R., Krakoff, I., Cohen, I. and Kowal, C. (1990). Phase I evaluation of [SP-4–3-(R)]-[1,1-cyclobutane-dicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N’)platinum(CI-973). Proc. Am. Assoc. Cancer Res., 31, A1170
Toffoli, G., Viel, A., Tumiotto, L., Buttazzi, P., Biscontin, G. and Boiocchi, M. (1989). Sensitivity pattern of normal and Ha-ras transformed NIH3T3 fibroblasts to antineoplastic drugs. Tumori, 75, 423–428
Trask, C., Silverstone, A., Ash, C. M., Earl, H., Irwin, C., Bakker, A., Tobias, J. S. and Souhami, R. L. (1991). A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. J. Clin. Oncol., 9, 1131–1137
Trump, D. L., Petros, W., Chaney, S., Smith, D. C., Fangmeier, J., Brown, T. D. and Goldberg, H. (1992). Phase I clinical trial and study of the pharmacokinetics and metabolism of ormaplatin (tetraplatin, NSC363812). Proc. Am. Assoc. Cancer Res., 33, A3217
Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Robins, H. I. and Spriggs, D. R. (1992). Phase I and pharmacokinetic study of ormaplatin. Proc. Am. Assoc. Cancer Res., 33, A3202
Van Beusichem, M. and Farrell, N. (1992). Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole, and quinoline. Crystal and molecular structure of trans-dichlorobis (thiazole)platinum(II). Inorg. Chem., 31, 634–639
Vermorken, J. B., ten Bokkel Huinink, W. W., McVie, J. G., van der Vijgh, W. J. F. and Pinedo, H. M. (1984). Clinical experience with 1,1-diaminocyclohexane(sulphate) platinum(II)(TNO6). In Hacker, M. P., Douple, E. B. and Krakoff, I. H. (Eds), Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Boston, pp. 330–343
Von Angerer, E., Bimbock, H. and Knebel, N. (1989). Platinum complexes with a selective action on estrogen receptor-positive mammary tumors. Anti-cancer Drug Design, 4, 21–35
Wagstaff, A. J., Ward, A., Benfield, P. and Heel, R. C. (1989). Carboplatin: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 37 (2), 163–186
Walker, M. C., Parris, C. N. and Masters, J. R. W. (1987). Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J. Natl Cancer Inst.., 79, 213–216
Waud, W. R. (1987). Differential uptake of cis-diamminedichloro platinum (II) by sensitive and resistant murine leukemia cells. Cancer Res., 47, 6549–6555
Willemse, P. H., Gieterra, J. A., Sleijfer, D. T., Mulder, N. H., de Vries, E. G., de Halleux, F., Rastogi, R. B. and Birkhofer, M. (1991). Activity of a third generation platinum compound zeWiplatin (CL 286,558) in patients with recurrent ovarian cancer. Proc. Am. Soc. Clin. Oncol., 10, A626
Wolf, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R. and Smyth, J. F. (1987). Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int. J. Cancer, 39, 696–702
Yarbo, J. W. (Ed.) (1992). Carboplatin (JM8) update: Current perspectives and future directions. Seminars in Oncology, 19(Suppl. 2), 1–164 Grune and Stratton, Philadelphia
Zinkewich-Peotti, K. and Andrews, P. A. (1992). Loss of cis-diamminedichloro platinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res., 52, 1902–1906
Editor information
Editors and Affiliations
Copyright information
© 1993 The contributors
About this chapter
Cite this chapter
McKeage, M.J., Kelland, L.R. (1993). New Platinum Drugs. In: Neidle, S., Waring, M.J. (eds) Molecular Aspects of Anticancer Drug-DNA Interactions. Topics in Molecular and Structural Biology. Palgrave, London. https://doi.org/10.1007/978-1-349-12356-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-349-12356-8_6
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-12358-2
Online ISBN: 978-1-349-12356-8
eBook Packages: EngineeringEngineering (R0)